Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine, cisplatin, disulfiram and copper in CTC_EMT-positive refractory metastatic breast cancer
2019-001957-16Phase 2Active
- Sponsor
- Národný onkologický ústav
- Start
- Jul 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine, cisplatin, disulfiram and copper sulfate in breast cancer, sponsored by Národný onkologický ústav. Primary endpoint: Objective response rate. Started Jul 2019; status: active.
02
Drugs
vinorelbinecisplatindisulfiramcopper sulfate
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-001957-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001957-16.